Emm Raises €7.7M Seed to Launch Smart Menstrual Cup and Connected Health Platform
Emm, the UK-based biowearable femtech startup developing what it describes as the world’s first “smart” menstrual cup paired with a connected app, has raised €7.7 million (about $9 million) in an oversubscribed Seed funding round as it prepares to bring its product to consumers and scale its technology for menstrual and reproductive health. The financing positions Emm among Europe’s more significant early-stage raises in the women’s health and connected device space, highlighting growing investor interest in solutions that deliver objective health data for previously underserved biological systems.
The Seed round was led by Lunar Ventures, with support from Labcorp Venture Fund, Tiny VC, BlueLion Global, Alumni Ventures, and a number of high-profile angel investors participating alongside the lead backers. The combination of specialized venture firms and strategic angels reflects both capital and domain expertise being directed toward Emm’s mission.
Founded in 2020 by CEO Jenny Button, Emm has spent the past five years developing its connected health platform, integrating ultra-thin advanced sensor technology with medical-grade silicone in a wearable device that functions like a menstrual cup but also captures physiological data throughout menstrual cycles. The accompanying mobile app aggregates and analyzes this data, helping users track key metrics such as cycle duration, frequency, and variation over time, and providing personalized insights into menstrual health. Emm positions these capabilities as a way to democratize data around reproductive health and give individuals more actionable knowledge about their own bodies — something often absent from traditional health tracking tools.
Jenny Button conceived Emm during the COVID-19 pandemic after realizing there were no mainstream technologies that offered objective, continuous data about menstrual health in the same way wearables like Oura Rings or Whoop bands did for other biometrics. That insight has driven product development and shaped Emm’s narrative around menstrual health as the “fifth vital sign” — emphasizing that menstruation is a fundamental health indicator, not a peripheral concern. Emm aims to provide users and clinicians with more clarity around reproductive biomarkers that might otherwise remain hidden or subjective.
The €7.7 million funding will support Emm’s final development, manufacturing, and commercial launch, with targeted availability in the UK in early 2026 and plans to expand into additional markets thereafter. Emm already boasts a sizeable waitlist of prospective users ahead of its official launch, signaling strong consumer interest. The company also plans to continue advancing clinical development and explore broader applications of its sensor data in reproductive health research, diagnosis, and potential therapeutic insights.
In addition to venture investment, Emm has secured non-dilutive grant funding geared toward women’s health innovation, supplementing its seed capital and enabling more robust development without further equity dilution. This combination of grants and private investment is often sought by startups working at the intersection of regulated health data and consumer technology, where proving clinical validity and technological reliability requires significant resources.
Emm’s approach focuses not only on providing cycle tracking data but also on delivering actionable insights that can influence health discussions between users and healthcare professionals. By aggregating high-resolution physiological data over multiple cycles, users can observe patterns, identify deviations from personal baselines, and potentially detect early signs of reproductive health conditions that are frequently under-diagnosed, such as endometriosis or hormonal imbalances. Emm’s sensor technology strives to capture this data with precision and comfort — an engineering challenge that has required extensive design iteration and user testing.
The backing from Lunar Ventures, Labcorp Venture Fund, Tiny VC, BlueLion Global, Alumni Ventures, and angel participants reflects a broader trend in the investment community toward backing female-focused health technologies that provide measurable value and data to users. Emm’s funding round is a milestone in FemTech financing, underscoring the potential for connected hardware-software solutions to unlock new understanding in areas of health historically overlooked by mainstream consumer devices.
With its product launch approaching and substantial capital raised, Emm is poised to transform how menstrual and reproductive health data is collected, interpreted, and used — shifting the narrative away from subjective experience to objective insights that support better health management, research, and clinical engagement.
